MedTrace Logo

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

NCT05696548 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-04-09

No results posted yet for this study

Summary

This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.

Conditions

  • Anaplastic Thyroid Cancer

Interventions

DRUG

Lenvatinib

Lenvatinib will be administered at a dose of 24mg as oral dose, one a day

DRUG

Nivolumab

Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    collaborator INDUSTRY

  • National Cancer Center Hospital East

    lead OTHER

Principal Investigators

  • Makoto Tahara, MD, PhD · National Cancer Center Hospital East

  • Iwao Sugitani, MD, PhD · Nippon Medical School Hospital

  • Naomi Kiyota, MD, PhD · Kobe University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-02
Primary Completion
2025-09-10
Completion
2026-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05696548 on ClinicalTrials.gov